Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Masupirdine

Phase 3Small molecule

SSuven Life Sciences Limited

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Agitation

NCT05397639

Clinical

Trials by Indication[1]

Agitation1 trial

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting·SSuven Life Sciences Limited·Phase 3·NCT05397639·375 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Masupirdine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Masupirdine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Masupirdine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suven Life Sciences Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSuven Life Sciences Limited

Related News